Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Sutro Biopharma Inc’s stock clocked out at $1.35, down -10.00% from its previous closing price of $1.50. In other words, the price has decreased by -$10.00 from its previous closing price. On the day, 1.17 million shares were traded.
Ratios:
To gain a deeper understanding of STRO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.09 and its Current Ratio is at 3.09. In the meantime, Its Debt-to-Equity ratio is 1.77 whereas as Long-Term Debt/Eq ratio is at 1.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on May 08, 2024, initiated with a Buy rating and assigned the stock a target price of $12.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $12.
On October 06, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $10.Oppenheimer initiated its Outperform rating on October 06, 2023, with a $10 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.69 while its Price-to-Book (P/B) ratio in mrq is 1.00.
Stock Price History:
Over the past 52 weeks, STRO has reached a high of $6.13, while it has fallen to a 52-week low of $1.32. The 50-Day Moving Average of the stock is -25.55%, while the 200-Day Moving Average is calculated to be -56.97%.
Shares Statistics:
A total of 82.40M shares are outstanding, with a floating share count of 74.44M. Insiders hold about 9.72% of the company’s shares, while institutions hold 68.90% stake in the company.
